Previous close | 0.3500 |
Open | 0.3500 |
Bid | 0.0000 |
Ask | 1.7000 |
Strike | 32.50 |
Expiry date | 2024-06-21 |
Day's range | 0.3500 - 0.3500 |
Contract range | N/A |
Volume | |
Open interest | 63 |
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV
Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.